Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Myeloid Malignancies Following Luminal Gastrointestinal Cancer: High Incidence of Deletion 5q and DNTM3A Mutations

Zachary D. Epstein-Peterson, MD, Sean M. Devlin, PhD, Eytan M. Stein, MD, Virginia M. Klimek, MD, Leonard B. Saltz, MD, Martin S. Tallman, MD

Blood (2017) 130 (Supplement 1): 1309.

https://doi.org/10.1182/blood.V130.Suppl_1.1309.1309

Published: 2017

Journal Articles

Invasive neighbors

Ambra Paolini, Goretta Bonacorsi

Blood (2013) 122 (25): 4011.

https://doi.org/10.1182/blood-2013-08-520494

Published: 2013

Journal Articles

Acute Leukemias Following a Diagnosis of Colorectal Cancer: Are They Therapy-Related?

Eytan M. Stein, MD, Vipul Pareek, MD, David Kudlowitz, Dan Douer, MD, Martin S Tallman, MD

Blood (2012) 120 (21): 1453.

https://doi.org/10.1182/blood.V120.21.1453.1453

Published: 2012

Journal Articles

2006 RADAR Report Card on Conversion Rates from Accelerated FDA Approval to Regular FDA Approval for Drugs Used To Treat Hematologic Malignancies: Policy Changes Continue To Be Needed.

Andrew J. Lurie, BGS, Mark V. Mai, Martin S. Tallman, MD, June McCoy, MD JD MPH, Charles L. Bennett, MD PhD MPP

Blood (2006) 108 (11): 3318.

https://doi.org/10.1182/blood.V108.11.3318.3318

Published: 2006

Journal Articles

Randomized, Double-Blind, Placebo-Controlled Trial of Epoetin Alfa (Procrit) in Patients with Rectal and Gastric Cancer Undergoing Chemo-Radiotherapy (CT/RT) Followed by Surgery: Early Termination of the Trial Due to Increased Incidence of Thrombo-Embolic Events (TEE).

Saroj Vadhan-Raj, MD, John M. Skibber, MD, Christopher Crane, MD, Carlos E. Bueso-Ramos, MD, Miguel A. Rodriguez-Bigas, MD, Barry W. Feig, MD, Edward H. Lin, MD, Jaffer A. Ajani, MD, Mindy Collard, Marcella M. Johnson, Stanley R. Hamilton, MD, Nora JanJan, MD

Blood (2004) 104 (11): 2915.

https://doi.org/10.1182/blood.V104.11.2915.2915

Published: 2004

Journal Articles

Thrombotic Thrombocytopenic Purpura as a Marker for Disease Progression in a Patient with Metastatic Rectal Cancer.

Jody L. Jordan, MD, Ruby Anne E. Deveras, MD, John Marshall, MD

Blood (2004) 104 (11): 4032.

https://doi.org/10.1182/blood.V104.11.4032.4032

Published: 2004

NARROW

Myeloid Malignancies Following Luminal Gastrointestinal Cancer: High Incidence of Deletion 5q and DNTM3A Mutations

Invasive neighbors

Acute Leukemias Following a Diagnosis of Colorectal Cancer: Are They Therapy-Related?

2006 RADAR Report Card on Conversion Rates from Accelerated FDA Approval to Regular FDA Approval for Drugs Used To Treat Hematologic Malignancies: Policy Changes Continue To Be Needed.

Randomized, Double-Blind, Placebo-Controlled Trial of Epoetin Alfa (Procrit) in Patients with Rectal and Gastric Cancer Undergoing Chemo-Radiotherapy (CT/RT) Followed by Surgery: Early Termination of the Trial Due to Increased Incidence of Thrombo-Embolic Events (TEE).

Thrombotic Thrombocytopenic Purpura as a Marker for Disease Progression in a Patient with Metastatic Rectal Cancer.

Email alerts

ASH Publications

American Society of Hematology

Myeloid Malignancies Following Luminal Gastrointestinal Cancer: High Incidence of Deletion 5q and DNTM3A Mutations

Invasive neighbors

Acute Leukemias Following a Diagnosis of Colorectal Cancer: Are They Therapy-Related?

2006 RADAR Report Card on Conversion Rates from Accelerated FDA Approval to Regular FDA Approval for Drugs Used To Treat Hematologic Malignancies: Policy Changes Continue To Be Needed.

Randomized, Double-Blind, Placebo-Controlled Trial of Epoetin Alfa (Procrit) in Patients with Rectal and Gastric Cancer Undergoing Chemo-Radiotherapy (CT/RT) Followed by Surgery: Early Termination of the Trial Due to Increased Incidence of Thrombo-Embolic Events (TEE).

Thrombotic Thrombocytopenic Purpura as a Marker for Disease Progression in a Patient with Metastatic Rectal Cancer.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only